# Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH

> **NCT04954742** · PHASE4 · TERMINATED · sponsor: **Heidelberg University** · enrollment: 30 (actual)

## Conditions studied

- Primary Pulmonary Arterial Hypertension
- Chronic Thromboembolic Pulmonary Hypertension

## Interventions

- **DRUG:** Riociguat

## Key facts

- **NCT ID:** NCT04954742
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-13
- **Primary completion:** 2025-08-13
- **Final completion:** 2025-08-13
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Strategic re-prioritization by the IMP supplier. Decision not safety-related
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954742, "Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04954742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*